There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ACADIA Pharmaceuticals (ACAD – Research Report), Beam Therapeutics (BEAM – Research Report) and Mirum Pharmaceuticals (MIRM – Research Report) with bullish sentiments.
ACADIA Pharmaceuticals (ACAD)
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on ACADIA Pharmaceuticals, with a price target of $27.00. The company’s shares closed last Wednesday at $17.13, close to its 52-week low of $16.16.
According to TipRanks.com, Fein is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ACADIA Pharmaceuticals with a $29.39 average price target, implying a 71.7% upside from current levels. In a report released yesterday, Citi also maintained a Buy rating on the stock with a $30.00 price target.
See the top stocks recommended by analysts >>
Beam Therapeutics (BEAM)
J.P. Morgan analyst Eric Joseph maintained a Buy rating on Beam Therapeutics on May 7 and set a price target of $45.00. The company’s shares closed last Wednesday at $22.24, close to its 52-week low of $16.95.
According to TipRanks.com, Joseph is a 3-star analyst with an average return of
Beam Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $46.67, which is an 115.0% upside from current levels. In a report issued on May 7, William Blair also maintained a Buy rating on the stock.
Mirum Pharmaceuticals (MIRM)
J.P. Morgan analyst Jessica Fye maintained a Buy rating on Mirum Pharmaceuticals today and set a price target of $31.00. The company’s shares closed last Wednesday at $25.04, close to its 52-week low of $23.14.
According to TipRanks.com, Fye is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mirum Pharmaceuticals with a $45.00 average price target, a 74.0% upside from current levels. In a report released today, JMP Securities also maintained a Buy rating on the stock with a $66.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ACAD:
- ACAD Earnings this Week: How Will it Perform?
- Acadia Pharmaceuticals announces Health Canada acceptance of trofinetide NDS
- Acadia Pharmaceuticals to present trofinetide findings in Rett syndrome at AAN
- Largest borrow rate increases among liquid names
- Acadia Pharmaceuticals price target lowered to $25 from $29 at JPMorgan
